image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Archived Events
Piper Sandler 34th Annual Healthcare Conference
November 30, 2022 at 4:30 PM EST
View Webcast
2022 RBC Capital Markets Global Healthcare Conference
May 18, 2022 at 11:00 AM EDT
View Webcast
21st Annual Needham Virtual Healthcare Conference
April 11, 2022 at 2:15 PM EDT
View Webcast
2nd Guggenheim Targeted Protein Degradation Day
March 16, 2022 at 11:00 AM EDT
View Webcast
32nd Annual Oppenheimer Healthcare Conference
March 15, 2022 at 4:00 PM EDT
View Webcast
11th Annual SVB Leerink Global Healthcare Conference
February 17, 2022 at 3:40 PM EST
View Webcast
Corporate Presentations
Scientific Presentation
Print Page
Email Alerts
RSS Feeds
Contact IR